Machavert Pharmaceuticals to Present at Biotech Showcase™, 2019 in San Francisco
AURORA, Colo., Jan. 4, 2019
AURORA, Colo., Jan. 4, 2019 /PRNewswire/ -- Machavert Pharmaceuticals, a preclinical stage pharmaceutical company focused on immuno-oncology and precision medicine cancer therapies, announced today that it will present at Biotech Showcase™ 2019, to be held January 7–9, during the most important week in healthcare at the Hilton San Francisco Union Square. Jakub Staszak-Jirkovsky, Ph.D. the Chief Executive Officer of Machavert will present as follows:
Date: Wednesday, January 9, 2019
Time: 9:15 (PST)
Room: Franciscan C (Ballroom Level)
Venue: Hilton San Francisco Union Square Hotel, 333 O'Farrell Street, San Francisco, CA (United States)
Machavert will present the key highlights of its two oncology assets currently under preclinical development; MP1115 and MP2019. Machavert's most developed asset, MP1115, is a bioactive immuno-oncology agent that also demonstrates a direct anti-cancer effect against solid tumors with KRAS mutation and liquid tumors, including indolent non-Hodgkin's lymphoma (NHL), acute myeloid leukemia (AML), and multiple myeloma models. The MP1115 nanoparticles were successfully shown to deliver a payload test compound to NHL cells and offer increased anti-tumor proliferative activity. MP2019 is a small molecule RAL GTPase inhibitor against solid and liquid tumors with KRAS mutation that is primarily being developed for non-small lung carcinoma treatment. MP2019 is also being combined with MP1115 for enhanced anti-cancer action.
Biotech Showcase™ is an investor and networking conference devoted to providing private and public biotechnology and life sciences companies with an opportunity to present to, and meet with, investors and executives in one place during the course of one of the industry's largest annual healthcare investor conferences, J.P. Morgan Annual Healthcare Conference.
About Machavert Pharmaceuticals
Machavert Pharmaceuticals is a preclinical stage drug development company focused on advanced therapies based on its proprietary bioactive phospholipid platform for the treatment of multiple cancers in hematology and solid tumor oncology. The phospholipid platform is also being combined with other therapeutics such as small molecules for precision medicine and immuno-oncology. Machavert's core focus is on difficult-to-treat driver mutations and other orphan indications in oncology.
For further information: Jakub Staszak-Jirkovsky, Chief Executive Officer, Machavert Pharmaceuticals, 720.859.4048, email@example.com
SOURCE Machavert Pharmaceuticals